-
APLT Dashboard
- Financials
- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Applied Therapeutics (APLT)
Company Profile
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 98.87 mm | 98.87 mm | 98.87 mm | 98.87 mm | 98.87 mm | 98.87 mm |
Cash burn (monthly) | 7.78 mm | (no burn) | 9.91 mm | 7.69 mm | 7.78 mm | 6.82 mm |
Cash used (since last report) | 41.32 mm | n/a | 52.68 mm | 40.86 mm | 41.32 mm | 36.24 mm |
Cash remaining | 57.55 mm | n/a | 46.19 mm | 58.01 mm | 57.55 mm | 62.63 mm |
Runway (months of cash) | 7.4 | n/a | 4.7 | 7.5 | 7.4 | 9.2 |
13F holders | Current |
---|---|
Total holders | 135 |
Opened positions | 52 |
Closed positions | 17 |
Increased positions | 33 |
Reduced positions | 32 |
13F shares | Current |
---|---|
Total value | 948.45 bn |
Total shares | 138.43 mm |
Total puts | 1.91 mm |
Total calls | 1.68 mm |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
ARE Alexandria Real Estate Equities | 12.56 mm | $113.41 mm |
Venrock Healthcare Capital Partners III | 11.66 mm | $105.25 mm |
JHG Janus Henderson | 10.54 mm | $89.66 bn |
MS Morgan Stanley | 9.90 mm | $84.19 bn |
VR Adviser | 9.82 mm | $83.51 bn |
Perceptive Advisors | 8.01 mm | $68.04 bn |
BlackRock | 6.94 mm | $59.01 bn |
BEN Franklin Resources | 6.80 mm | $60.46 bn |
Propel Bio Management | 6.57 mm | $55.83 bn |
Knoll Capital Management | 5.57 mm | $47.38 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Mar 25 | Riccardo Perfetti | Common Stock | Sell | Dispose S | No | No | 0.44 | 10,366 | 4.56 k | 890,409 |
4 Mar 25 | Funtleyder Leslie D. | Common Stock | Sell | Dispose S | No | No | 0.44 | 14,502 | 6.38 k | 390,459 |
4 Mar 25 | Constantine Chinoporos | Common Stock | Sell | Dispose S | No | No | 0.44 | 447 | 196.68 | 271,436 |
6 Feb 25 | Funtleyder Leslie D. | Common Stock | Sell | Dispose S | No | No | 0.61 | 22,950 | 14.00 k | 404,961 |
6 Feb 25 | Riccardo Perfetti | Common Stock | Sell | Dispose S | No | No | 0.61 | 86,078 | 52.51 k | 900,775 |